ABSTRACT
Objective To compare prevalence of COVID-19 testing and test outcomes among individuals with psychiatric disorders to those without such diagnoses, and to examine the associations of testing probability and outcome with psychiatric diagnosis categories.
Design Large population-based study to perform association analyses of psychiatric disorder diagnoses with COVID-19 testing probability and such test results, by using two-sided Fisher exact tests and logistic regressions.
Setting UK Biobank.
Participants 1 474 men and women of British ancestry that had been tested for COVID-19, with a mean age of 58.2 years.
Main outcome measures COVID-19 testing probability and COVID-19 test results.
Results Individuals with psychiatric disorders were overrepresented among the 1 474 UKB participants with test data: 23% of the COVID-19 test sample had a psychiatric diagnosis compared to 10% in the full cohort (p<0.0001). This overrepresentation persisted for each of the specific psychiatric disorders tested. Furthermore, individuals with a psychiatric disorder (p=0.01), particularly with substance use disorder (p<0.005), had negative test results significantly more often than individuals without psychiatric disorders. Sensitivity analyses confirmed our results.
Conclusions In contrast with our hypotheses, UKB participants with psychiatric disorders have been tested for COVID-19 more frequently than individuals without a psychiatric history, pleading against the notion that limited health care access is preventing them from undergoing testing. Among those tested, test outcomes were more frequently negative for UKB participants with psychiatric disorders than in others, countering arguments that people with psychiatric disorders are particularly prone to contract the virus.
What is already known on this topic (2–3 sentences) We searched PubMed using the terms "COVID-19" combined with "mental health", "psychiatric disorder" or "mental illness" for all articles published in any language before April 21st, 2020. Two hundred articles were retrieved, most of which related to the Chinese experience when dealing with the pandemic, including the mental health impact of the COVID-19 pandemic on general population mental health and healthcare workers; and on advancing mental healthcare resources in times of crisis. No evidence was found on testing patterns for severe acute respiratory syndromes (e.g. COVID-19, SARS, MERS) or Ebola virus on people with psychiatric disorders.
What this study adds (2–3 sentences) We highlight a positive association between psychiatric disorders and the likelihood of being tested for COVID-19, as well as an association between psychiatric disorders and negative results. The results thus counter arguments that patients with psychiatric disorders are suffering from limited health care access preventing them from undergoing testing. Additionally, these are important findings as they carry the potential to reduce stigma: while people in the general population may be concerned that patients with psychiatric disorders do not comply with containment measures and are susceptible to contract COVID-19, our findings may help counter such concerns.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; JPE declares he has served as CME speaker for Lundbeck, all of which were activities unrelated to this work, while the rest of the authors declare no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.
Funding Statement
No external funding sources sponsored or participated in the study design; data collection, analysis, and interpretation; in the writing of the report; and in the decision to submit the paper for publication.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
This research has been conducted using the UK Biobank Resource under Application Number 55392.
